生物标志物用于良恶性肺结节鉴别诊断的研究进展

doi:10.3969/j.issn.2096-8493.20210035

摘要/Abstract

摘要：

生物标志物检测是一种操作简单且便于监测随访的检测方法,广泛应用于肺结节的定性诊断及其恶性演进过程的研究中。不同生物标志物对于恶性肺结节的诊断特异度和敏感度不同,多种生物标志物的联合检测或低剂量螺旋CT的联合评估可显著提高恶性肺结节的诊断效能。作者回顾性总结了生物标志物在肺结节良恶性鉴别诊断中的临床价值及研究进展,为肺结节患者的临床诊治和分层管理提供合理建议。

关键词: 肺肿瘤, 生物学标记, 诊断, 鉴别

Abstract:

Biomarker detection is a simple and convenient method for monitoring and follow-up, which is widely used in the qualitative diagnosis of pulmonary nodules and the study of malignant evolution. Different biomarkers have different specificity and sensitivity in the diagnosis of malignant pulmonary nodules. The combined detection of multiple biomarkers or the evaluation combined with low-dose spiral CT can significantly improve the diagnostic efficiency of malignant pulmonary nodules. The clinical value and research progress of biomarkers in the differential diagnosis of benign and malignant pulmonary nodules were reviewed to provide reasonable suggestions for clinical diagnosis and treatment, and hierarchical management of patients with pulmonary nodules.

Key words: Lung neoplasms, Biomarkers, Diagnosis, differential

崔凯, 张晓菊. 生物标志物用于良恶性肺结节鉴别诊断的研究进展[J]. 结核与肺部疾病杂志, 2021, 2(3): 273-276. doi: 10.3969/j.issn.2096-8493.20210035

CUI Kai, ZHANG Xiao-ju. Research progress on the application of biomarkers in differential diagnosis of benign and malignant pulmonary nodules[J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 273-276. doi: 10.3969/j.issn.2096-8493.20210035

参考文献 33

[1]	National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365(5):395-409. doi: 10.1056/NEJMoa1102873. doi: 10.1056/NEJMoa1102873 URL
[2]	Yang DW, Zhang Y, Hong QY, et al. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients. Cancer, 2015, 121 Suppl 17:3113-3121. doi: 10.1002/cncr.29551. doi: 10.1002/cncr.29551 URL
[3]	Hao C, Zhang G, Zhang L. Serum CEA levels in 49 different types of cancer and noncancer diseases. Prog Mol Biol Transl Sci, 2019, 162:213-227. doi: 10.1016/bs.pmbts.2018.12.011. doi: 10.1016/bs.pmbts.2018.12.011
[4]	奚小祥, 吕必宏, 叶婷, 等. NSE、Cyfra21-1、CEA及CA125在孤立性肺结节诊断中的价值. 实用临床医药杂志, 2015, 19(21):41-43,51. doi: 10.7619/jcmp.201521011. doi: 10.7619/jcmp.201521011
[5]	Li X, Zhang Q, Jin X, et al. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study: Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules. World J Surg Oncol, 2017, 15(1):107. doi: 10.1186/s12957-017-1171-y. doi: 10.1186/s12957-017-1171-y pmid: 28545454
[6]	中华医学会呼吸病学分会肺癌学组, 中国肺癌防治联盟专家组. 肺结节诊治中国专家共识(2018年版). 中华结核和呼吸杂志, 2018, 41(10):763-771. doi: 10.3760/cma.j.issn.1001-0939.2018.10.004. doi: 10.3760/cma.j.issn.1001-0939.2018.10.004
[7]	Chen F, Li J, Qi X. Diagnostic value of CYFRA 21-1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease. J Cancer Res Ther, 2018, 14(Supplement):S400-S404. doi: 10.4103/0973-1482.174180. doi: 10.4103/0973-1482.174180
[8]	Yu Z, Lu H, Si H, et al. A Highly Efficient Gene Expression Programming (GEP) Model for Auxiliary Diagnosis of Small Cell Lung Cancer. PLoS One, 2015, 10(5):e0125517. doi: 10.1371/journal.pone.0125517. doi: 10.1371/journal.pone.0125517 URL
[9]	Molina R, Marrades RM, Augé JM, et al. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. Am J Respir Crit Care Med, 2016, 193(4):427-437. doi: 10.1164/rccm.201404-0603OC. doi: 10.1164/rccm.201404-0603OC URL
[10]	牛安琳, 罗艳容, 刘功成, 等. 6种肿瘤标志物联合检测在辅助肺癌诊断及分型中的应用价值. 中国卫生检验杂志, 2019, 29(10):1235-1237,1241. doi: cnki:sun:zwjz.0.2019-10-027. doi: cnki:sun:zwjz.0.2019-10-027
[11]	倪莲芳, 刘新民. 血清肿瘤标记物对孤立性肺结节良恶性的诊断价值. 北京大学学报(医学版), 2014, 46(5):707-710. doi: 10.3969/j.issn.1671-167X.2014.05.008. doi: 10.3969/j.issn.1671-167X.2014.05.008
[12]	Kupert E, Anderson M, Liu Y, et al. Plasma secretory phospholipase A2-Ⅱa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer, 2011, 11:513. doi: 10.1186/1471-2407-11-513. doi: 10.1186/1471-2407-11-513 pmid: 22151235
[13]	Hou H, Xu Z, Zhang H, et al. Combination diagnosis of multi-slice spiral computed tomography and secretary phospholipase A2-Ⅱa for solitary pulmonary nodules. J Clin Lab Anal, 2018, 32(2):e22250. doi: 10.1002/jcla.22250. doi: 10.1002/jcla.22250 URL
[14]	He Y, Jiang Z, Tong F, et al. Experimental study of peripheral-blood pro-surfactant protein B for screening non-small cell lung cancer. Acta Cir Bras, 2017, 32(7):568-575. doi: 10.1590/s0102-865020170070000008. doi: 10.1590/s0102-865020170070000008 URL
[15]	Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida F, Sun N, et al. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncol, 2018, 4(10):e182078. doi: 10.1001/jamaoncol.2018.2078. doi: 10.1001/jamaoncol.2018.2078 URL
[16]	Yanagita K, Nagashio R, Jiang SX, et al. Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer. Am J Pathol, 2018, 188(6):1328-1333. doi: 10.1016/j.ajpath.2018.03.007. doi: S0002-9440(17)30976-8 pmid: 29751934
[17]	Yin W, Zhu J, Ma B, et al. Overcoming Obstacles in Pathological Diagnosis of Pulmonary Nodules through Circulating Tumor Cell Enrichment. Small, 2020, 16(25):e2001695. doi: 10.1002/smll.202001695. doi: 10.1002/smll.202001695
[18]	Zheng J, Ye X, Liu Y, et al. The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer. BMC Cancer, 2020, 20(1):106. doi: 10.1186/s12885-020-6524-1. doi: 10.1186/s12885-020-6524-1 pmid: 32041568
[19]	Ried K, Eng P, Sali A. Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study. Asian Pac J Cancer Prev, 2017, 18(8):2275-2285. doi: 10.22034/APJCP.2017.18.8.2275. doi: 10.22034/APJCP.2017.18.8.2275
[20]	Zheng W, Zhao J, Tao Y, et al. MicroRNA-21: A promising biomarker for the prognosis and diagnosis of non-small cell lung cancer. Oncol Lett, 2018, 16(3):2777-2782. doi: 10.3892/ol.2018.8972. doi: 10.3892/ol.2018.8972 pmid: 30127862
[21]	史佳民, 刘娣, 范理宏. 七种微小RNA在良恶性肺结节鉴别诊断中的价值. 同济大学学报(医学版), 2019, 40(2):169-173. doi: 10.16118/j.1008-0392.2019.02.007. doi: 10.16118/j.1008-0392.2019.02.007
[22]	Zhang H, Mao F, Shen T, et al. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncol Lett, 2017, 13(2):669-676. doi: 10.3892/ol.2016.5462. doi: 10.3892/ol.2016.5462 pmid: 28356944
[23]	Xi K, Wang W, Wen Y, et al. Combining Plasma miRNAs and Computed Tomography Features to Differentiate the Nature of Pulmonary Nodules. Front Oncol, 2019, 9:975. doi: 10.3389/fonc.2019.00975. doi: 10.3389/fonc.2019.00975 URL
[24]	Tamkovich S, Laktionov P. Cell-surface-bound circulating DNA in the blood: Biology and clinical application. IUBMB Life, 2019, 71(9):1201-1210. doi: 10.1002/iub.2070. doi: 10.1002/iub.2070 pmid: 31091350
[25]	Xing W, Sun H, Yan C, et al. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules. BMC Cancer, 2021, 21(1):263. doi: 10.1186/s12885-021-08002-4. doi: 10.1186/s12885-021-08002-4 URL
[26]	Massion PP, Healey GF, Peek LJ, et al. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. J Thorac Oncol, 2017, 12(3):578-584. doi: 10.1016/j.jtho.2016.08.143. doi: S1556-0864(16)30928-5 pmid: 27615397
[27]	Ren S, Zhang S, Jiang T, et al. Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology, 2017, 7(2):e1384108. doi: 10.1080/2162402X.2017.1384108. doi: 10.1080/2162402X.2017.1384108 URL
[28]	Johnson MK, Wu S, Pankratz DG, et al. Analytical validation of the Percepta genomic sequencing classifier; an RNA next gene-ration sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules. BMC Cancer, 2021, 21(1):400. doi: 10.1186/s12885-021-08130-x. doi: 10.1186/s12885-021-08130-x pmid: 33849470
[29]	Billatos E, Vick JL, Lenburg ME, et al. The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection. Clin Cancer Res, 2018, 24(13):2984-2992. doi: 10.1158/1078-0432.CCR-16-3187. doi: 10.1158/1078-0432.CCR-16-3187 pmid: 29463557
[30]	Pavel AB, Campbell JD, Liu G, et al. Alterations in Bronchial Airway miRNA Expression for Lung Cancer Detection. Cancer Prev Res (Phila), 2017, 10(11):651-659. doi: 10.1158/1940-6207.CAPR-17-0098. doi: 10.1158/1940-6207.CAPR-17-0098 URL
[31]	AEGIS Study Team. Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection. J Natl Cancer Inst, 2017, 109(7):djw327. doi: 10.1093/jnci/djw327. doi: 10.1093/jnci/djw327
[32]	Yang D, Zhang X, Powell CA, et al. Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study. Cancer, 2018, 124(2):262-270. doi: 10.1002/cncr.31020. doi: 10.1002/cncr.31020 URL
[33]	裴东方, 陈少武, 李静. 低剂量螺旋CT联合肿瘤标志物CEA,SCC-Ag,ProGRP,NSE对良恶性孤立性肺结节的鉴别诊断价值. 实用癌症杂志, 2021, 36(4):614-617. doi: 10.3969/j.issn.1001-5930.2021.04.024. doi: 10.3969/j.issn.1001-5930.2021.04.024